| Quantitative analysis of lymphocyte differentiation and proliferation in vitro using carboxyfluorescein diacetate succinimidyl ester J Hasbold, AV Gett, JS Rush, E Deenick, D Avery, J Jun, PD Hodgkin Immunology and cell biology 77 (6), 516-522, 1999 | 188 | 1999 |
| Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation F Bornancin, F Renner, R Touil, H Sic, Y Kolb, I Touil-Allaoui, JS Rush, ... The Journal of Immunology 194 (8), 3723-3734, 2015 | 137 | 2015 |
| Staggered AID‐dependent DNA double strand breaks are the predominant DNA lesions targeted to Sµ in Ig class switch recombination JS Rush, SD Fugmann, DG Schatz International immunology 16 (4), 549-557, 2004 | 127 | 2004 |
| B cells activated via CD40 and IL‐4 undergo a division burst but require continued stimulation to maintain division, survival and differentiation JS Rush, PD Hodgkin European journal of immunology 31 (4), 1150-1159, 2001 | 126 | 2001 |
| Targeting co-stimulatory molecules in autoimmune disease NM Edner, G Carlesso, JS Rush, LSK Walker Nature Reviews Drug Discovery 19 (12), 860-883, 2020 | 124 | 2020 |
| Expression of activation-induced cytidine deaminase is regulated by cell division, providing a mechanistic basis for division-linked class switch recombination JS Rush, M Liu, VH Odegard, S Unniraman, DG Schatz Proceedings of the National Academy of Sciences 102 (37), 13242-13247, 2005 | 114 | 2005 |
| Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study BA Fisher, A Szanto, WF Ng, M Bombardieri, MG Posch, AS Papas, ... The Lancet Rheumatology 2 (3), e142-e152, 2020 | 106 | 2020 |
| TNF leads to mtDNA release and cGAS/STING-dependent interferon responses that support inflammatory arthritis J Willemsen, MT Neuhoff, T Hoyler, E Noir, C Tessier, S Sarret, ... Cell reports 37 (6), 2021 | 94 | 2021 |
| A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion F Cordoba, G Wieczorek, M Audet, L Roth, MA Schneider, A Kunkler, ... American Journal of Transplantation 15 (11), 2825-2836, 2015 | 90 | 2015 |
| Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody J Ristov, P Espie, P Ulrich, D Sickert, T Flandre, M Dimitrova, ... American Journal of Transplantation 18 (12), 2895-2904, 2018 | 78 | 2018 |
| Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers CG Begley, M Ashton, J Baell, M Bettess, MP Brown, B Carter, ... Science Translational Medicine 13 (612), eabd5524, 2021 | 71 | 2021 |
| First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody P Espié, YL He, P Koo, D Sickert, C Dupuy, E Chokoté, R Schuler, ... American Journal of Transplantation 20 (2), 463-473, 2020 | 70 | 2020 |
| A novel anti-CD40 monoclonal antibody, iscalimab, for control of Graves hyperthyroidism—a proof-of-concept trial GJ Kahaly, MN Stan, L Frommer, P Gergely, L Colin, A Amer, ... The Journal of Clinical Endocrinology & Metabolism 105 (3), 696-704, 2020 | 69 | 2020 |
| Cross-linking surface Ig delays CD40 ligand-and IL-4-induced B cell Ig class switching and reveals evidence for independent regulation of B cell proliferation and differentiation JS Rush, J Hasbold, PD Hodgkin The Journal of Immunology 168 (6), 2676-2682, 2002 | 52 | 2002 |
| The Novel Anti-CD40 Monoclonal Antibody CFZ533 Shows Beneficial Effects in Patients with Primary Sjogren's Syndrome: A Phase IIa Double-Blind, PlaceboControlled Randomized Trial B Fisher, M Zeher, WF Ng, M Bombardieri, M Posch, AS Papas, AM Farag, ... Arthritis & Rheumatology 69, 2017 | 44 | 2017 |
| Silent Fc variants of anti-CD40 antibodies C Heusser, R James, K Vincent US Patent 8,828,396, 2014 | 41 | 2014 |
| Blockade of CD40–CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren’s syndrome G Wieczorek, M Bigaud, S Pfister, M Ceci, K McMichael, C Afatsawo, ... Annals of the rheumatic diseases 78 (7), 974-978, 2019 | 38 | 2019 |
| Non‐redundancy of cytidine deaminases in class switch recombination SD Fugmann, JS Rush, DG Schatz European journal of immunology 34 (3), 844-849, 2004 | 27 | 2004 |
| The logic of intercellular communication in the immune system PD Hodgkin, J Rush, AV Gett, G Bartell, J Hasbold Immunology and cell biology 76 (5), 448-453, 1998 | 27 | 1998 |
| Nonclinical safety assessment of CFZ533, a Fc-silent anti-CD40 antibody, in cynomolgus monkeys P Ulrich, T Flandre, P Espie, D Sickert, T Rubic-Schneider, DA Shaw, ... Toxicological Sciences 166 (1), 192-202, 2018 | 21 | 2018 |
